ACHE and Alzheimer disease: The focus on disease-modifying therapies (DMTs) has shifted from managing symptoms to altering the disease progression and targeting the mechanisms underlying AD, such as Aβ plaques, acetylcholinesterase, and tau tangle accumulation.